From: BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study
Patient no. | HB-EGF in serum (pg/mL) | HB-EGF in abdominal fluid (pg/mL) | Serum CA125 (IU/mL) | Anti-diphtheria toxin antibodies (IU/mL) | Efficacy | ||||
---|---|---|---|---|---|---|---|---|---|
Pre-Tx | Post-Tx | Pre-Tx | Post-Tx | Pre-Tx | Post-Tx | Pre-Tx | Post-Tx | ||
1 | 1971 | 196 | 2169 | 106 | 291 | 137 | <0.01 | 2.56 | SD |
2 | 556 | 349a | 416 | 560a | 1411 | 3487 | <0.01 | 124 | PD |
3 | 297 | 172 | 593 | 292 | 46 | 50 | <0.01 | >131 | SD |
4 | 267 | 85 | 143 | 34 | 1408 | 2217 | 0.04 | >131 | PR |
5 | 51 | 101 | 55 | 399 | 267 | 600 | 0.03 | 31.1 | SD |
6 | 74 | 109 | 109 | 171 | 254 | 158 | <0.01 | 81.9 | PD |
7 | 67 | 79 | 130 | ND | 2813 | 3983 | <0.01 | 0.06 | PD |
8 | 162 | 141a | 140 | 132a | 3894 | 5147 | 0.13 | 20.5 | PD |
9 | 231 | 130 | 237 | 66 | 1856 | 3984 | 0.01 | 1.02 | PD |
10 | 247 | 140 | ND | ND | 40 | 63 | <0.01 | >41.0 | SD |
11 | 67 | 155a | ND | ND | 16 | 94 | <0.01 | >6.56 | SD |